Navigation Links
Global Rainmakers Brings Cutting-Edge Biometric Security Products to Reality
Date:10/27/2009

NEW YORK, Oct. 27 /PRNewswire/ -- Global Rainmakers, Inc., an intellectual property holding company and advanced R&D laboratory, today announced that the company has exited its "stealth" mode and is prepared to actively commercialize its suite of technologies designed to leverage cutting-edge biometric security offerings.

During the past four years, the company has spent tens of millions of dollars to develop and deploy a series of core--but expandable--technologies built around identity management solutions. Global Rainmakers has worked with the Pentagon, U.S. Air Force and the Department of Homeland Security, as well as banking and financial services companies such as Bank of America. The company was founded by Chairman and CEO Hector Hoyos and Keith Hanna, D.Phil., Chief Technology Officer and Executive Vice President.

Global Rainmakers has carefully developed its intellectual property portfolio to support a wide range of biometric products that can meet the demands of both public and private sector businesses. Biometrics products are designed to uniquely recognize humans based on one or more intrinsic physical or behavioral trait, which could include finger print, voice, DNA and iris recognition. Biometrics solutions are often leveraged in identity access management and control systems.

"Biometrics has been more promise than reality for the past 20 years," said Hector Hoyos, Global Rainmakers Chairman and CEO. "We've spent considerable time and resources to develop biometric technologies that can be put into the field today and have a significant impact on the activities of our clients. The key to our technologies is their scalable nature. Our initial iris identification offerings have already been field-tested with both governmental and corporate clients. The expectation is
'/>"/>

SOURCE Global Rainmakers, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology news :

1. Global warming may spur increased growth in Pacific Northwest forests
2. Epigentek Develops a New Method of Measuring Global DNA Methylation
3. Amid rising concerns, 600 global biodiversity experts meet in Cape Town Oct. 13-16
4. Global public health the focus of scientific conference
5. Reportlinker Adds Proteomics: Technologies and Global Markets Report
6. WCC Smart Search & Match and Priv-ID Announce Global Collaboration
7. Cybernetwork to help K-State researchers study tallgrass prairie, respond to global warming
8. NRL begins Southeast Asia study of aerosols linked to global warming
9. Half of the fish consumed globally is now raised on farms, study finds
10. 2009 Lasker Awards recognize promise of stem cells -- global market could top $700 million
11. Early spring time for Edinburgh? Study predicts effect of global warming on spring flowers

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2009)... Current research suggests that a common oral bact...ted report by Nichols et al, "Unique Lipids from a...LR2 Ligands Capable of Enhancing Autoimmunity," ap...Journal of Pathology . , Multiple sclerosis (MS)...ain and spinal cord, affects nearly 1 in 700 peopl...
(Date:11/23/2009)...The only swine vaccine available for the H1N1 viru... with the virus. The vaccination marks the first t...d with the pandemic flu., Iowa State University,...ped the vaccine this summer and has been shipping ...s and Illinois for several weeks., The latest va...
(Date:11/23/2009)...vember 16, 2009 -- A USDOE and USDA study conclude...pland, and cropland pasture could be converted fro...ses, such as switchgrass, from which biomass could...omically viable production of a perennial grass mo...mass are removed annually is expected to require n...
Breaking Biology News(10 mins):Factors from common human bacteria may trigger multiple sclerosis 2Iowa State researcher produces, ships only H1N1 vaccine available for swine 2Switchgrass produces biomass efficiently 2UK Identity and Passport Service and IBM Sign 7 year National Biometric Identity Service 28NBIS 29 Contract 9215 1UK Identity and Passport Service and IBM Sign 7 year National Biometric Identity Service 28NBIS 29 Contract 9215 2Obama 3A Too Many Still Die from Diseases That Shouldnt Kill Them 51397 1Obama 3A Too Many Still Die from Diseases That Shouldnt Kill Them 51397 2Mayo Clinic Study Using Structural MRI May Help Accurately Diagnose Dementia Patients 51392 1Mayo Clinic Study Using Structural MRI May Help Accurately Diagnose Dementia Patients 51392 2
...h, and still the University of Wisconsin-Madison S...requests. Since 1998, the school,s oncology depar...r dogs diagnosed with melanoma. Though it is sti...over the nation have wanted to participate in the ...heir pet. , After promising results from work done...
...we carry this activity out through the placenta an...velopment, the lungs of the foetus are filled with... activates this respiration surface. But the main ...ungs are not well formed. Moreover, they often lac...pids that avoids the lungs folding in on themselve...
...billion-base human genome play a vital role in a b...chers from the Wellcome Trust Sanger Institute and...r Medical Research, together with international co...ps of differences implicated in disease as well as... , The Major Histocompatibility Complex (MHC) con...
Other Biology News:Canine cancer vaccine program shows early promise 2Liquid ventilation 2Researchers map of genetic variations implicated in disease 2Researchers map of genetic variations implicated in disease 3
(Date:11/19/2009)...SEATTLE, Nov. 19 Omeros ...ited financial results for the third quarter ended...ptember 30, 2009, Omeros reported a net loss of $3...et loss of $7.4 million, or $2.54 per share, for t...September 30, 2009, the Company reported a net los...
(Date:11/19/2009)..., ,, BETHESDA, Md., Nov. 19 /PRNewswire-Fir...an innovator in biotechnology for diabetes therapy...lting services to food, supplement, biotechnology ...losed the previously reported $6.3 million registe... 2,760,870 shares of its common stock and warrants...
(Date:11/19/2009)...BETHESDA, Md., Nov. 19 S... in biotechnology for diabetes therapy, and a prov...es to food, supplement, biotechnology and pharmace...uesday,s Annual Meeting of Shareholders. ,, At ...(Nasdaq: SPEX ) elected the following members to ...
(Date:11/19/2009)..., MUNSTER, Germany, November 19 /PRNewswire/ ...filed on November 16th, 2009 Flibanserin in the,in...nesia in Parkinson,s,disease for orphan drug statu...EMEA). Levodopa-induced dyskinesia is a complicati...,s and a serious burden to some of those,affected,...
Breaking Biology Technology:Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 3Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 4Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 5Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 6Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 7Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 8Spherix Announces the Closing of $6.3 Million Registered Direct Offering 2Spherix Announces the Closing of $6.3 Million Registered Direct Offering 3Spherix Announces Results of Annual Shareholders Meeting 2Spherix Announces Results of Annual Shareholders Meeting 3Spherix Announces Results of Annual Shareholders Meeting 4MONITORING FORCE GmbH Requests Acknowledgment of Flibanserin as "Orphan Drug" 2
... Time -, SAN FRANCISCO, Nov. 10 Medivation, Inc....progress and financial,results for the quarter end...ented another quarter of significant,achievement a... partnering,agreement with Pfizer for Dimebon. Thi...d-class partner capable of maximizing global,comme...
... Discuss the Data and Ongoing ...Nov. 10 Sangamo,BioSciences, Inc. (Nasdaq: SGMO ...1 clinical trial, one of Sangamo,s three Phase 2 c...am to develop SB-509 for diabetic,neuropathy (DN)....f the,drug is well tolerated in subjects with mild...
...es of Non-Core Product Lines -, HOPKINTON, Mass.,...LP ) today reported third quarter financial,result...divestitures: the,sale of its AutoTrace(R) product...he sale of its Pharmaceutical Development and Qual...on for $15.8 million. Revenues for the,quarter wer...
Other Biology Technology:Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update 2Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update 3Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update 4Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update 5Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update 6Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update 7Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update 8Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601 2Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601 3Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601 4Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601 5Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601 6Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 2Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 3Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 4Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 5Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 6Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 7Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 8Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 9Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 10Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 11
...ein Phosphatase-2A (PPase-2A) is a serine/threonin... It is isolated as the heterodimer of 60kDa (A) an...phorylate the a-subunit of phosphorylase kinase. W...oad substrate specificity and may play a regulator...
...oskan is a high performance spectral scanning mult.... With the advanced SkanIt Software it offers supe...y assay development. Varioskan provides unlimited ...ime-resolved fluorescence and photometric assays a...
...ctively condenses and traps a wide variety of solv... pump oil. Easy-to-use glass condensation flask (G...self contained jar for easy draining. Rapid coolin...4 o C temperature traps high volatile solvents ...
Immulon 2HB from Thermo Scientific
Biology Products: